|
Gender (n, %)
|
0.172
|
0.678
|
|
Male
|
27 (64.3)
|
47 (68.1)
|
|
Female
|
15 (35.7)
|
22 (31.9)
|
|
Primary disease (n, %)
|
0.016
|
0.899
|
|
AML
|
22 (52.4)
|
37 (53.6)
|
|
ALL
|
20 (47.6)
|
32 (46.4)
|
|
Disease status at HSCT (n, %)
|
1.873
|
0.392
|
|
First CR
|
19 (45.2)
|
39 (56.5)
|
|
Second and other CR
|
16 (38.1)
|
18 (26.1)
|
|
Relapse
|
7 (16.7)
|
12 (17.4)
|
|
Disease status at HSCT (n, %)
|
1.332
|
0.248
|
|
First CR
|
19 (45.2)
|
39 (56.5)
|
|
Other
|
23 (54.8)
|
30 (43.5)
|
|
Extramedullary infiltration (n, %)
|
2.538
|
0.111
|
|
Yes
|
8 (19.0)
|
6 (8.7)
|
|
No
|
34 (81.0)
|
63 (91.3)
|
|
Conditioning regimen (n, %)
|
0.082
|
0.775
|
|
Bu/Cy-based
|
30 (71.4)
|
51 (73.9)
|
|
TBI/Cy-based
|
12 (28.6)
|
18 (26.1)
|
|
Gender of donor-recipient (n, %)
|
5.669
|
0.017
|
|
Identical
|
19 (45.2)
|
47 (68.1)
|
|
Different
|
23 (54.8)
|
22 (31.9)
|
|
Donor-recipient ABO compatibility (n, %)
|
0.014
|
0.907
|
|
Compatible
|
19 (45.2)
|
32 (46.4)
|
|
Incompatible
|
23 (54.8)
|
37 (53.6)
|
|
Abnormal markers
|
NA
|
NA
|
|
t(9;22)
|
8 (19.0)
|
13 (18.8)
|
|
MLL/AF4
|
1 (2.4)
|
3 (4.3)
|
|
FLT3/ITD
|
2 (4.8)
|
1 (1.4)
|
|
MRD
|
0.014
|
0.906
|
|
Yes
|
12 (28.6)
|
19 (27.5)
|
|
No
|
30 (71.4)
|
50 (72.5)
|
|
MNC (× 108/kg)
|
11.74 (3.98–31.03)
|
14.57 (3.57–47.11)
|
NA
|
NA
|
|
CD34 + cells(× 106/kg)
|
5.84 (3.43–23.30)
|
8.33 (3.07–35.7)
|
NA
|
NA
|
|
Time for implantation of neutrophils (d)
|
12 (9–19)
|
13 (10–26)
|
NA
|
NA
|
|
Time for implantation of PLT(d)
|
13 (8–30)
|
13 (9–26)
|
NA
|
NA
|
